AXL and hepatocellular carcinoma: Our findings provide novel mechanistic evidence of AXL-suppressed TNF-α/IFN-α signaling and a proof-of-concept with preclinical model to support the clinical testing of AXL inhibition in combination with immunotherapy for HCC patients who progress on first-line TKI treatment.